DarioHealth: Q2 Earnings Insights

Shares of DarioHealth DRIO moved higher by 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 423.08% year over year to ($0.68), which beat the estimate of ($1.40).

Revenue of $1,787,000 up by 8.24% from the same period last year, which beat the estimate of $1,550,000.

Outlook

DarioHealth hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 12, 2020

Time: 09:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/36466

Technicals

52-week high: $18.84

52-week low: $0.20

Price action over last quarter: Up 123.19%

Company Profile

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.

DRIO Logo
DRIODarioHealth Corp
$0.7050-1.81%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
13.86
Growth
3.14
Quality
Not Available
Value
29.70
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...